AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02243735
Drug: ferric(III)carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
Trial: NCT02648711
Drug: CRLX101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion CRLX101 weekly
Trial: NCT00358436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
Trial: NCT01046825
Drug: COP, COPD M3, CYM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted.
Trial: NCT03929640
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg tablet every 6 hours
Trial: NCT03929640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet every 6 hours
Trial: NCT03929640
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 600 mg tablet every 6 hours
Trial: NCT01681199
Drug: Fluvastatin extended release tablet
RxNorm normalized name: fluvastatin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01746277
Drug: combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
Trial: NCT01746277
Drug: Sequenced group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
Trial: NCT01327027
Drug: Placebo; Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
Trial: NCT00305539
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00610311
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
Trial: NCT02458677
Drug: PRX003
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02615340
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
Trial: NCT02615340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
Trial: NCT01860807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00746434
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream
Trial: NCT01274559
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 oral 1 g tablet of placebo to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of placebo to be taken together in the evening or at bedtime with food for the next 8 weeks.
Trial: NCT00280085
Drug: Arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02575170
Drug: Ringer's lactate solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml of Ringer's lactate solution
Trial: NCT02215330
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03600649
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/m2/day on Days 1 thru 5 of a 21-day cycle
Trial: NCT02106494
Drug: APF530
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02106494
Drug: APF530 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02129816
Drug: Bryophyllum
RxNorm normalized name: Bryophyllum (Argento Cultum)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00753883
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 20 mg/QD for 6 Weeks.
Trial: NCT00720902
Drug: growth hormone releasing hormone (GHRH) & arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.
Trial: NCT02650986
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02208037
Drug: Methotrexate (ARM with Maraviroc)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of maraviroc. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
Trial: NCT02208037
Drug: Methotrexate (ARM with Bortezomib)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of bortezomib. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
Trial: NCT01556698
Drug: NVN1000
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01556698
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01551316
Drug: MN-221
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This drug is intravenously infused and delivers 1200 mcg to the patient in 1 hour duration. This dose is repeated over 4 days (Day 1 1200 mcg once; Day 2 1200 mcg twice; Day 3 1200 mcg twice; Day 4 1200 mcg once).
Trial: NCT01551316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention consists of a placebo intravenous infusion, one that contains no active medication. During the double-blind procedure, patients will be infused with placebo intravenously one time on Day 1, twice on Days 2 and 3, and one time on Day 4.
Trial: NCT02208037
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hydration prior to cyclophosphamide may be given according to institutional standards.~Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide \[50 mg/kg ideal body weight (IBW); if ABW \< IBW, use ABW\] will be given on Day 3 post-transplant (between 60 and 72 hours after the start of the HSCT) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
Trial: NCT01836198
Drug: LY2409021
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01836198
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01334944
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
Trial: NCT02305381
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
Trial: NCT04380298
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30ml of local infiltration solution containing 60mg ropivacaine
Trial: NCT04380298
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30ml of local infiltration solution containing 0.1mg epinephrine
Trial: NCT00369681
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02192723
Drug: Typical antipsychotic
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks
Trial: NCT02627898
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, 400mg 1 time daily with the first bite of eat meal
Trial: NCT01847976
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.
Trial: NCT02163655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills, identical to the intervention (furosemide pills), will be administered every 24 hour for a maximum of five days
Trial: NCT02308098
Drug: Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02308098
Drug: Symbicort Turbuhaler 320/9 ug/inhalation 1inh
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02308098
Drug: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02308098
Drug: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01582503
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous repeating dose
Trial: NCT04603833
Drug: SHR3680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SHR3680
Trial: NCT03516045
Drug: 18F-AlF-NOTA-neurotensin
RxNorm normalized name: NEUROTENSIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection of the radioligand 18F-AlF-NOTA-neurotensin
Trial: NCT02205541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28.~ECZ or placebo will be administrated intravenously as a 30-minute injection
Trial: NCT00041756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet, twice daily for for one year
Trial: NCT04472988
Drug: Treatment as Usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
Trial: NCT01073800
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03082716
Drug: Custodiol Solution
RxNorm normalized name: CUSTODIOL HTK SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After cross clamping patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
Trial: NCT03082716
Drug: Blood cardioplegia
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After cross clamping patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
Trial: NCT01329939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age-dependent dose, nightly, 24 weeks
Trial: NCT00185224
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 treatment cycles of 28 days each (no tablet-free intervals); Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27 - 28: Placebo
Trial: NCT05859802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking a placebo pill two times day
Trial: NCT01118455
Drug: Anti-Epileptic Drug (AED)
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject has tried at least 2 appropriate AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 had been tolerated at normal doses.
Trial: NCT00757978
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule of placebo twice a day
Trial: NCT02969629
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04369950
Drug: 2% lidocaine with 1:200,000 epinephrine and epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidurals will be dosed with 2% lidocaine with 1:200,000 epinephrine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
Trial: NCT03430063
Drug: SDREGN2810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose intravenous (IV) infusion
Trial: NCT03430063
Drug: SDREGN2810/ipi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy dose IV
Trial: NCT03430063
Drug: HDREGN2810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose IV
Trial: NCT00544791
Drug: melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg, oral, daily dose for 6 months
Trial: NCT00544791
Drug: placebo like melatonin tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01995019
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml intra-articular placebo
Trial: NCT01584492
Drug: CHF 1535 50/6 (2 inhalations)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
Trial: NCT01584492
Drug: CHF 1535 50/6 (4 inhalations)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
Trial: NCT01584492
Drug: Placebo (6 inhalations)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo via pMDI
Trial: NCT05099913
Drug: Deanxit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central neuromodulators was applied in refractory FD patients for different time
Trial: NCT04538989
Drug: RZ358 Sequential Group Cohort 1
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)
Trial: NCT04538989
Drug: RZ358 Sequential Group Cohort 2
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)
Trial: NCT04538989
Drug: RZ358 Sequential Group Cohort 3
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)
Trial: NCT04538989
Drug: RZ358 Sequential Group Cohort 4
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)
Trial: NCT00790920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, single bolus over 1 - 2 minutes on 1st day
Trial: NCT00087659
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03075904
Drug: ALXN1830
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via IV infusion.
Trial: NCT04360876
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo delivered intravenously on the same dosing schedule as dexamethasone
Trial: NCT01691040
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT03120299
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
Trial: NCT01797978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04620031
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading Dose：0.1 mg/kg, infused with 4 min ± 30 s； Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h. Range of maintenance dose: 0.06-0.8 mg/kg/h
Trial: NCT01099683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive rectal suppository containing placebo
Trial: NCT00317876
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00317876
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02854358
Drug: mixed powder of A. digitata and M. sylvestris
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02854358
Drug: Hypozalix spray (artificial saliva)
RxNorm normalized name: Dunaliella salina extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypozalix spray (artificial saliva)
Trial: NCT00815347
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
Trial: NCT00010842
Drug: Essential fatty acids
RxNorm normalized name: essential fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00817336
Drug: D Serine
RxNorm normalized name: Wall-associated serine proteinase
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg/day
Trial: NCT00817336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00866918
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00866918
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally